Labeling of polypeptides with technetium-99m using a dextran spacer
Radioimmunoscintigraphy and other forms of scintigraphy are becoming increasingly important as tools in detection and evaluation of cancer diseases. Several radionuclides can be considered as radiolabel; however, 99mTc may be the most suitable because of easy availability and near ideal physical properties. This study describes how dextran is coupled to a monoclonal anticytokeratin antibody, epidermal growth factor, and somatostatin through stable amine bonds. The dextran moiety could then be labeled with 40-62 MBq of 99mTc. The labeling efficiency was 60-94%, determined by gel filtration or TLC. The specific binding could be considerably preserved after the dextranation, the antibody retained > 90% of its activity, epidermal growth factor bound with > 90% specificity to receptor-expressing tumor cells, and somatostatin showed approximately 40% specific binding to rat adrenal homogenates. Because somatostatin only has a transient half-like in vivo, the in vivo plasma half-life of somatostatin-dextran was tested in normal female Sprague-Dawley rats. The result showed a strong enhancement of the plasma half-life that was dependent on two compartments, 4 and 8 h.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1995 |
|---|---|
| Erschienen: |
1995 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Cancer research - 55(1995), 23 Suppl vom: 01. Dez., Seite 5710s-5713s |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Holmberg, A [VerfasserIn] |
|---|
| Themen: |
51110-01-1 |
|---|
| Anmerkungen: |
Date Completed 11.01.1996 Date Revised 23.11.2016 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM074699830 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM074699830 | ||
| 003 | DE-627 | ||
| 005 | 20231222023254.0 | ||
| 007 | tu | ||
| 008 | 231222s1995 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0249.xml |
| 035 | |a (DE-627)NLM074699830 | ||
| 035 | |a (NLM)7493332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Holmberg, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Labeling of polypeptides with technetium-99m using a dextran spacer |
| 264 | 1 | |c 1995 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.1996 | ||
| 500 | |a Date Revised 23.11.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Radioimmunoscintigraphy and other forms of scintigraphy are becoming increasingly important as tools in detection and evaluation of cancer diseases. Several radionuclides can be considered as radiolabel; however, 99mTc may be the most suitable because of easy availability and near ideal physical properties. This study describes how dextran is coupled to a monoclonal anticytokeratin antibody, epidermal growth factor, and somatostatin through stable amine bonds. The dextran moiety could then be labeled with 40-62 MBq of 99mTc. The labeling efficiency was 60-94%, determined by gel filtration or TLC. The specific binding could be considerably preserved after the dextranation, the antibody retained > 90% of its activity, epidermal growth factor bound with > 90% specificity to receptor-expressing tumor cells, and somatostatin showed approximately 40% specific binding to rat adrenal homogenates. Because somatostatin only has a transient half-like in vivo, the in vivo plasma half-life of somatostatin-dextran was tested in normal female Sprague-Dawley rats. The result showed a strong enhancement of the plasma half-life that was dependent on two compartments, 4 and 8 h | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Dextrans |2 NLM | |
| 650 | 7 | |a Somatostatin |2 NLM | |
| 650 | 7 | |a 51110-01-1 |2 NLM | |
| 650 | 7 | |a Epidermal Growth Factor |2 NLM | |
| 650 | 7 | |a 62229-50-9 |2 NLM | |
| 650 | 7 | |a Keratins |2 NLM | |
| 650 | 7 | |a 68238-35-7 |2 NLM | |
| 650 | 7 | |a Technetium |2 NLM | |
| 650 | 7 | |a 7440-26-8 |2 NLM | |
| 700 | 1 | |a Marquez, M |e verfasserin |4 aut | |
| 700 | 1 | |a Westlin, J E |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 55(1995), 23 Suppl vom: 01. Dez., Seite 5710s-5713s |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:1995 |g number:23 Suppl |g day:01 |g month:12 |g pages:5710s-5713s |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 1995 |e 23 Suppl |b 01 |c 12 |h 5710s-5713s | ||